Navigation Links
Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052)
Date:5/12/2011

ially if their partner refuses to use condoms consistently."

Recently released data from another study, HPTN 043, demonstrated that community mobilization boosts HIV testing in developing countries and is one option for effectively increasing coverage of HIV testing services. The HPTN is evaluating a test, link to care, plus treat approach for prevention of HIV transmission in HPTN 065, a study currently underway in the USA. This study will demonstrate the population-level impact of increased knowledge of HIV status and linkage to care on HIV transmission.

About HPTN 052

HPTN 052 is a randomized, controlled trial designed to evaluate the effectiveness of antiretroviral therapy to prevent the sexual transmission of HIV in serodiscordant couples. The trial is conducted by the HIV Prevention Trials Network (HPTN) and funded by the National Institute for Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH). Additional support was provided by the NIAID-funded Adult Clinical Trials Group. The antiretroviral drugs used in the study were made available by Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; and Merck & Co., Inc.

About HIV Prevention Trials Network (HPTN)

The HIV Prevention Trials Network (HPTN) is a partnership between scientists and communities around the world to develop, evaluate, and implement cutting-edge biomedical, behavioral, and structural interventions to reduce the transmission of HIV. HPTN uses randomized controlled clinical trials, designed and conducted according to the highest scientific and ethical standards, to identify the best combinations of interventions for the populations at highest risk of HIV infection worldwide. HPTN is largely funded by National Institute for Allergy and Infectious Diseases with additional funding from National Institute on Drug Abuse and Nation
'/>"/>

SOURCE HIV Prevention Trials Network
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH
2. Genus Oncology, LLC Announces Initiation of Phase I Trial of GO-203-2c in Patients With Solid Tumors
3. Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
4. Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer
5. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
6. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
7. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
8. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
9. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
10. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
11. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 RoundTable Healthcare Partners ("RoundTable"), an ... healthcare industry, announced today the sale of Vesta ... Lubrizol, a Berkshire Hathaway company, is a specialty ... customers in the global transportation, industrial and consumer ... Vesta is an ISO-13485 certified medical ...
(Date:8/1/2014)... NORTH CHICAGO , Ill. and PALO ... (NYSE: ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced ... in the cystic fibrosis (CF) community through the CFChef ... to September 15, 2014, as part of AbbVie,s CFChef ... caregivers – to encourage patients to maintain a healthy ...
(Date:8/1/2014)... Mass. , Aug. 1, 2014  NxStage Medical, Inc. ... dialysis products, today announced that Jeffrey H. Burbank , ... Officer, will present at the 34 th Annual Canaccord ... Boston, MA , on Wednesday, August 13 th ... will be made available at http://ir.nxstage.com/ .  ...
Breaking Medicine Technology:RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2
... 6, 2012  PAREXEL International Corporation (NASDAQ: PRXL ... that Ramita Tandon, Global Head, Late Phase Clinical Trials ... Operations at PAREXEL will address innovative approaches to late ... ( SCOPE ), to be held February 7-9, 2012 ...
... New York, February 6, 2012 In the news ... of USD 6.8 billion in 2015, China Osteoporosis Market Will be ... 11:30 GMT, by Transparency Market Research over PR Newswire, we are ... "Market Size of USD 6.8 billion" has been changed to "Market ...
Cached Medicine Technology:PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 2PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 3PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 4CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 2CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 3CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 4
(Date:8/1/2014)... at the University of California, San Diego School of ... in chili peppers produces chronic activation of a ... a reaction that ultimately reduces the risk of colorectal ... 1, 2014 issue of The Journal of Clinical ... TRPV1, was originally discovered in sensory neurons, where it ...
(Date:8/1/2014)... 2014 Stryker hip lawsuits ( ... 2012 Rejuvenate and ABG II Modular-Neck Hip Stem ... Bergen County Superior Court, Bernstein Liebhard LLP reports. ... Court has issued a Final Amended Stipulated ... hard copy and electronic materials produced by any ...
(Date:8/1/2014)... MN (PRWEB) August 01, 2014 Summer is ... are most active during the summer, and they can be ... Minnesota is ready to help all their customers get rid ... between 3,000 and 6,000 eggs in the summer, which is ... to live in tall grass and woodland areas and carry ...
(Date:8/1/2014)... 01, 2014 The American Telemedicine ... Harper (R-MS), and Peter Welch (D-VT), for their ... Telehealth Parity Act of 2014, which improves telemedicine ... effort to improve healthcare access and affordability using ... of ATA. "These cost-saving provisions are critical to ...
(Date:8/1/2014)... The "Antimicrobial Coatings Market by ... Oxide, Titanium Dioxide, and Zinc Omadine), Application (Indoor ... & Beverages, Textiles, and others), & Geography (North ... and Forecasts to 2018" analyzes the Antimicrobial Coatings ... trends in the diverse geographical regions. , Browse ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4
... NEW YORK, March 19 More than 90% ... market, due to the lack of,effectiveness or adverse ... positives could be avoided with pre-clinical tests using ... to,Kalorama Information,s new report Stem Cells: Worldwide Markets ...
... 19, 2008 The Russell Berrie Foundation has donated ... Hospital, as part of a focused effort to provide ... research initiatives, toward a cure, the Medical Center gratefully ... diabetes is a disease in which the bodys failure ...
... on Food Safety and Quality, ANN ARBOR, ... Spartan Stores is the largest supermarket chain in ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070816/DCTH039LOGO ), Spartan ... and,retailers, is going beyond standard Food Code requirements ...
... of Howard G. Smith,announces that a securities class action ... purchased the publicly traded securities of Vertex,Pharmaceuticals Inc. ("Vertex" ... 2007 and November 2, 2007, inclusive (the "Class Period"). ... District Court for the,District of Massachusetts., The Complaint ...
... join panel after key ground rules established, OAKLAND, ... employed by Sutter Health,s,California Pacific Medical Center and St. ... Panel formed to develop a plan for the future ... panel after its co-chairs, with the,agreement of city leaders ...
... altered form of natural compound found in heparin samples ... officials say they,ve identified the contaminant found in the ... allergic reactions and possibly 19 deaths in the United ... oversulfated condroitin sulfate, but U.S. Food and Drug Administration ...
Cached Medicine News:Health News:Stem Cell Technology Offers Promise of Huge Savings for Drug Developers 2Health News:Columbia University Medical Center/NYPH receive $28 million donation toward curing diabetes 2Health News:Columbia University Medical Center/NYPH receive $28 million donation toward curing diabetes 3Health News:Spartan Stores Becomes Largest U.S. Supermarket Chain to Receive NSF Shop Fresh(TM) Certification 2Health News:Spartan Stores Becomes Largest U.S. Supermarket Chain to Receive NSF Shop Fresh(TM) Certification 3Health News:UHW Joins Blue Ribbon Panel on the Future of St. Luke's Hospital 2Health News:FDA Identifies Contaminant in Blood-Thinning Drug 2Health News:FDA Identifies Contaminant in Blood-Thinning Drug 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: